Skip to content

Price / sales at other companies

Exelixis logo
ExelixisEXEL
4.8×+0.3×
Cytokinetics logo
CytokineticsCYTK
76.7×-171×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
149.5×-487×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.5×+0.6×
Incyte logo
IncyteINCY
3.5×+0.8×
Summit Therapeutics logo
Summit TherapeuticsSMMT
8,008.9×+7,666×

Other financials

Income statement

See full
Revenue$164.9M+4.9%
Gross profit$162.0M+4.7%
Operating income-$49.6M-1,552%
Net income-$31.8M-255%
EPS (diluted)-$0.30-276%

Balance sheet

See full
Cash & equivalents$110.0M+21.1%
Total debt$9.6M+41.0%
Total equity$638.0M-6.6%
Total assets$814.9M-3.7%

Cash flow

See full
Operating cash flow-$16.8M-452%
CapEx$201.0K+93.3%
Free cash flow-$17.0M-464%

Valuation

See full
Market cap$8.58B-64.4%
Enterprise value$8.48B-65.0%
P/E181.2×+1.3×

Profitability

See full
Gross margin98.3%-0.2pp
Operating margin-1.1%-17.2pp
Net margin6.2%-13.4pp
FCF margin15.6%-10.2pp

Returns & leverage

See full
Return on equity7.2%-14.6pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Calculated from Corcept Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corcept Therapeutics's price / sales?
Corcept Therapeutics (CORT) reported price / sales of 5.6× in Q1 2026.
How has Corcept Therapeutics's price / sales changed year-over-year?
Corcept Therapeutics's price / sales decreased by 68.3% year-over-year, from 17.6× to 5.6×.
What is the long-term trend for Corcept Therapeutics's price / sales?
Over 5 years (2020 to 2025), Corcept Therapeutics's price / sales has grown at a -10.8% compound annual growth rate (CAGR), from 8.5× to 4.8×.
What does price / sales mean?
How many dollars investors pay for each dollar of the company's annual sales.
How do you interpret price / sales?
Useful when earnings are negative or volatile (e.g. early-stage or cyclical firms). Only comparable across companies with similar margins — a sales dollar is worth more at a high-margin business.
How does price / sales compare across companies?
Best compared within a margin cohort; a software P/S and a retailer P/S are not directly comparable.